# A Prospective, Single-arm, Phase II Clinical Trial of Becotatug Vedotin for Injection Combined With Pucotenlimab Injection as a First-line Treatment for Platinum-intolerant Advanced Head and Neck Squamous Cell Carcinoma

> **NCT07628855** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center** · enrollment: 30 (estimated)

## Conditions studied

- HNPCC

## Interventions

- **DRUG:** Becotatug Vedotin (recombinant humanized anti-EGFR mAb-MMAE conjugate) combined with Pucotenlimab (recombinant humanized anti-PD-1 mAb)

## Key facts

- **NCT ID:** NCT07628855
- **Lead sponsor:** Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-14
- **Primary completion:** 2028-08-30
- **Final completion:** 2028-08-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07628855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07628855, "A Prospective, Single-arm, Phase II Clinical Trial of Becotatug Vedotin for Injection Combined With Pucotenlimab Injection as a First-line Treatment for Platinum-intolerant Advanced Head and Neck Squamous Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07628855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*